Skip to main content
. 2021 Nov 27;13(23):5968. doi: 10.3390/cancers13235968

Figure 1.

Figure 1

Structure and mechanism of action of tebentafusp. Tebentafusp comprises an engineered T cell receptor targeting an epitope of Gp-100 presented by HLA-A*02:01 cells, linked to an anti-CD3 single-chain variable fragment that can engage T cells. The interaction induces polyclonal T cell recruitment and activation, the release of cytokines and cytolytic mediators, and, ultimately, the killing of target cells. Gp-100, glycoprotein 100; HLA, human leukocyte antigen; MHC, major histocompatibility complex; TCR, T cell receptor.